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A B S T R A C T   
It has previously been shown that preeclampsia is associated with disturbed hemostasis and that extracellular 
vesicles (EVs) play important role in the regulation of hemostatic homeostasis. Thus, we hypothesized that the 
altered procoagulant characteristics of circulating platelet-derived EVs may contribute to the disturbed hemo-
stasis in preeclampsia. 
Using multicolor flow cytometry, we have analyzed both tissue factor expressing procoagulant EVs and 
platelet-derived EV subpopulations derived from resting and activated thrombocytes by examining them in 
plasma samples of preeclamptic patients and pregnancy-matched healthy individuals. 
Compared to pregnancy-matched healthy individuals in preeclamptic patients a significantly (p < 0.05) higher 
ratio of Annexin-V positive activated platelets and a higher number of CD142+ tissue factor bearing procoagulant 
EVs were found, whereas the absolute amount of circulating CD41a+ platelet-derived EVs and CD62P+/CD41a+
EVs produced by activated thrombocytes was significantly lower in the plasma of preeclamptic women. In the 
plasma samples, there was no significant difference in the amount of CD63+ platelet-derived EVs. 
We propose that increased platelet activation and tissue factor expression of platelet derived extracellular 
vesicles may contribute to the hypercoagulable state observed in preeclampsia.   
1. Introduction 
Hemostasis is a complex process that relies on the balance between 
procoagulant and anticoagulant factors. Human pregnancy is associated 
with increased procoagulant activity, which consists of the increased 
production of procoagulant proteins and the lower levels of natural 
anticoagulant and fibrinolytic agents (Brenner, 2004; McLean et al., 
2012). Preeclampsia occurs in 2–8 % of human pregnancies and is 
diagnosed by the new onset of hypertension after the 20th gestational 
week. It is accompanied by proteinuria, maternal renal dysfunction, 
liver damage, neurological symptoms, hemolysis, thrombocytopenia or 
fetal growth restriction. In addition, hemolysis, elevated liver enzymes, 
low platelets (HELLP) syndrome is also part of the preeclampsia 
spectrum (Brown et al., 2018). 
In preeclampsia, the abnormal early development of placental 
vasculature renders the placenta chronically hypoxic-ischemic and the 
defective placenta later produces anti-angiogenic substances, which 
impair the endothelium of the maternal circulation. As a consequence, 
clinically manifested maternal hypertension, proteinuria and various 
end-organ damage can develop (Staff, 2019). In addition to placental 
hypoperfusion, hemostatic imbalance plays an important role in the 
pathogenesis of preeclampsia. It is characterized by increased coagula-
tion, altered fibrinolysis and extensive platelet activation, fibrin depo-
sition, consumptive thrombocytopenia, and coagulopathy. The 
hypercoagulable state of preeclamptic pregnant women is associated 
with higher ratio of circulating activated platelets and 
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platelet-monocyte aggregates (Macey et al., 2010). On the other hand, 
the anti-thrombin activity in the early onset of preeclampsia has been 
proposed to be a predictor of the time of delivery (Morikawa et al., 
2019). 
The “platelet-like activity of serum” has already been described in 
1955 (O’Brien, 1955), although its subcellular character was first shown 
by electron microscopy in 1967 by Peter Wolf (Wolf, 1967). The pro-
coagulant activity of the “platelet dust” was related to membrane 
phospholipids, and was designated as platelet factor 3 (PF3) (Hardisty 
and Hutton, 1966). In the recent years, it has become well-known, that 
vesiculation is a general cell biological process and extracellular vesicles 
(EV) are constitutively produced by different resting and activated cells 
(Redman and Sargent, 2008). Platelet-derived EVs (P-EV) have an 
important role both in hemostasis and in immune response via the 
regulation of inflammation and endothelial function (Lopez et al., 
2019). 
The translational aspect of the above and clinical assertion of the 
disturbed hemostasis is the finding that aspirin - a long established an-
tiplatelet agent – is increasingly used in high-risk pregnancies in the last 
decade. Indeed, preeclampsia may be prevented by taking low dose 
aspirin starting from the first trimester until near term (Poon et al., 
2019). This underlines the importance to reveal the potential patho-
physiological links between platelet function and the development of 
preeclampsia. Based on the above, we hypothesized that preeclampsia 
alters the procoagulant characteristics of circulating platelet derived 
extracellular vesicles. Thus, we aimed to analyze circulating procoagu-
lant EV patterns in the plasma of preeclamptic patients and 
pregnancy-matched healthy women. 
2. Materials and methods 
2.1. Patients 
Fifteen preeclamptic patients (PE) and fifteen third trimester healthy 
pregnant women (HP) were enrolled into this pilot study. Preeclampsia 
was defined as a new onset high blood pressure (more than 140 mmHg 
systolic or 90 mmHg diastolic) in the presence of significant proteinuria 
according to the ISSHP guideline published in 2014 (Tranquilli et al., 
2014). Prenatal care (routine obstetrical examination) was provided at 
the Department of Obstetrics and Gynecology, Semmelweis University 
in Budapest, Hungary. None of the patients took aspirin nor applied 
heparin. The study was approved by the Ethical Community of the 
Semmelweis University according to the Helsinki Declaration and was 
also authorized by the Ethic Committee of Medical Research Council of 
Hungary (ETT-TUKEB: 10147-4/2015/EKU (93/2014). 
The clinical data of the patients participating in this study show 
significant (p < 0.05) difference between the preeclamptic and control 
groups in terms of maternal age, gestational age at birth and birth 
weight of the neonate, whereas the gestational age at the time of sample 
collection was not different (Table 1). All these data indicate a pre-
eclamptic condition in this group of pregnant women. 
2.2. Sample collection 
Peripheral venous blood samples were collected from the median 
cubital vein during the pregnancy, but always before the onset of labor. 
Vacutainer® Brand Plus Acid Citrate Dextrose (ACD) Tubes of Greiner 
Bio One International GmbH (Germany) were used for preventing the in 
vitro platelet activation and EV production (Gyorgy et al., 2014). Sam-
ples were transferred at room temperature into the flow cytometric 
laboratory immediately after blood collection. Platelet count was 
measured by using an automated blood cell counter at the Department of 
Laboratory Medicine, Semmelweis University. 
2.3. Separation of platelet free plasma for EV measurements 
Platelet-free plasma (PFP) was prepared using a 3-step centrifugation 
procedure: 1) 2000 rpm centrifugation for 5 min at room temperature 
for depletion of peripheral blood cells; 2) repeated centrifugation at 
2500 g for 5 min at 20 ◦C for preparation of PFP. PFP samples were 
stored at − 80 ◦C for future experiments. 
2.4. Flow cytometric analysis of platelets and platelet derived circulating 
EVs 
Unseparated plasma samples (1:500 dilution in sterile filtered 
phosphate buffered saline - PBS) were stained by phycoerythrin conju-
gated anti-CD42b (von Willebrand factor receptor) and fluorescein iso-
thiocyanate (FITC) labelled Annexin V for the determination of resting 
and activated thrombocytes (Supplementary Fig. 1: gating strategy). 
PBS-diluted PFP samples (1:500 dilution in sterile filtered PBS) were 
used for the identification of platelet derived EVs. Anti-CD41a FITC 
(gpIIb/IIIa complex), anti-CD42b Pe (von Willebrand factor receptor) 
were used for the determination of platelet derived EVs. Activation state 
of circulating platelet derived EVs were analyzed by anti-CD62 P APC (P- 
selectin), anti-CD142 Pe (tissue factor), anti-CD63 Pe (tetraspanin-30) 
and Annexin V FITC staining. Anti-CD41a, anti-CD42b, anti-CD62 P and 
anti-CD63 antibodies were manufactured by BD Biosciences Pharmin-
gen (San Jose, CA, USA). Annexin V and anti-CD142 antibody were 
produced by Sony Biotechnology Inc. (Tokyo, Japan). The „Direct 
Immunofluorescence Staining of Cells Using a Lyse/No-Wash Proced-
ure” protocol of BD Biosciences was adapted for the staining of exofacial 
molecules of EVs. The presence of EVs was confirmed by differential 
detergent lysis (Gyorgy et al., 2011). Those events that did not disappear 
in the presence of 0.1 % Triton-X 100 were rejected from analysis. Count 
Check Beads (Sysmex Partec GmbH) were used as an internal standard 
for the calculation of absolute number of circulating platelet-derived 
EVs. 
Measurements were carried out by using a FACSCalibur flow cy-
tometer (BD, San Jose, CA, USA) on the day of the staining. Forward 
Table 1 
Patient clinical data.   
Preeclamptic third 
trimester pregnant 
women (n = 15) 
Healthy third 
trimester pregnant 





30.4 ± 5.3 34.4 ± 3.7 p < 0.05 
Primiparity (%) 53 % 27 % p < 0.05 
Systolic blood 
pressure (mmHg, 
mean ± SD) 
158 ± 20.5 114.3 ± 8.6 p < 0.05 
Diastolic blood 
pressure (mmHg, 
mean ± SD) 
94.7 ± 14.6 71.1 ± 5.9 p < 0.05 
Urine protein 
(mean ± SD) 
3490 ± 1886 mg/24 h not detectable – 
Early onset PE (%) 533% (8/15) n/a – 
HELLP syndrome 
(%) 
20 % (3/15) n/a – 
Gestational age at 
sampling (weeks, 
mean ± SD) 
33.0 ± 4.4 34.1 ± 3.4 ns 
Gestational age at 
birth (weeks, 
mean ± SD) 








25.3 ± 7.8 22.9 ± 3.2 ns 
n/a = not applicable, ns = not significant. 
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(FSC) and side scatter parameters were set in log scale, and threshold 
was set at the SSC parameter. EV gating was accomplished by pre-
liminary standardization experiments using Megamix-Plus SSC beads 
(Biocytex, France) and was optimized with 1 μm Silica Beads Fluo-Green 
Green (Kisker Biotech GmbH & Co; Steinfurt, Germany). CellQuestPro 
software (BD, San Jose, CA, USA) was used for both the acquisition and 
analysis. 
Circulating platelets were defined on the basis of their CD42b 
expression, while activated and resting thrombocytes were distin-
guished by the exofacial presence or absence of phosphatidylserine 
(Annexin-V positivity). 
Circulating platelet derived EVs were demonstrated by exofacial 
labelling of gpIIb/IIIa complex (CD41a) and von Willebrand factor re-
ceptor (CD42b). Exofacial CD62 P and CD63 were used for the isolation 
of platelet derived EVs produced by activated thrombocytes. 
The procoagulant activity of platelet derived EVs was examined in 
the presence of tissue factor (TF) on their surface. 
2.5. Statistical analysis 
Microsoft Excel (2010) software was used for data processing. Sta-
tistical differences between the studied groups were tested using 
“GraphPad Prism 6′′ software (San Diego, CA). If datasets have passed 
the test of normality, statistical significances were analyzed by two- 
tailed Student’s t-test, and descriptive statistics have been shown as 
means ± standard error of mean (SEM). If datasets have not passed the 
test of normality, statistical significances were analyzed by the non- 
parametric Mann-Whitney test, and descriptive statistics have been 
shown as medians and interquartile range (IQR). Statistical significance 
was defined as p <0.05. 
3. Results 
3.1. Platelet count 
The mean value of platelet count was significantly lower in the 
preeclamptic group (168.9 G/l ± 19.08, mean ± SEM) compared to 
healthy pregnant group (242.1 G/l ± 9.90) (p < 0.05, n = 15 in both 
groups) (Fig. 1). 
3.2. Flow cytometric analysis of circulating platelets 
3.2.1. Activation state of circulating platelets 
Significantly higher ratio of activated (CD42b+/AnnexinV+) plate-
lets was detected in the plasma of preeclamptic patients (median: 15.23 
%, IQR: 2.50–21.19 %, n = 15) compared to third trimester healthy 
pregnant women (median: 4.05 %, IQR: 1.72–6.48 %, n = 15)(p < 0.05) 
(Fig. 2). 
3.3. Flow cytometric analysis of platelet-derived extracellular vesicles (P- 
EVs) 
3.3.1. Tissue factor (TF, CD142) 
Significantly higher amount of procoagulant TF bearing (CD142+) 
circulating P-EVs was detected in the plasma of preeclamptic patients 
(20,638 events/μL ± 7143, mean ± SEM, n = 10) than in healthy 
pregnancy (5283 events/μL ± 788, mean ± SEM, n = 13) (p < 0.03) 
(Fig. 3). 
3.3.2. GpIIb/IIIa complex (CD41a) 
The median value of circulating CD41a + PEVs produced by acti-
vated thrombocytes was significantly lower in the plasma of pre-
eclamptic patients (median: 11,903 events/μL IQR: 8041–19533, n =
15) compared to third trimester healthy women (median: 54,297 
events/μL, IQR: 30395–116438, n = 15) (p < 0.05) (Fig. 4). 
3.3.3. P-Selectin (CD62) 
The absolute amount of circulating CD62 P/CD41a double positive 
P-EVs produced by activated thrombocytes was significantly lower in 
the plasma of preeclamptic patients (median: 191 events/μL IQR: 
62–677, n = 15) compared to third trimester healthy women (median: 
2717 events/μL, IQR: 997–5445, n = 15) (p < 0.05) (Fig. 4). 
3.3.4. Tetraspanin (CD63) 
We observed a higher amount of circulating tetraspanin positive 
(CD63+) P-EVs in preeclamptic patients (median = 4107 events/μL IQR: 
2095–19247, n = 13) compared to third trimester healthy pregnant 
women (median: 3352 events/μL, IQR: 1110–5716, n = 13), but the 
difference was not statistically significant p = 0.15) (Fig. 5), 
4. Discussion 
The salient novel finding of the present study is that compared to 
Fig. 1. Platelet count in preeclamptic patients and healthy controls (n = 15, 
mean ± SEM) * p < 0.05. 
Fig. 2. Activation state of circulating platelets in preeclamptic patients and 
healthy controls (medians and IQRs, n = 15) * p < 0.05. 
Fig. 3. Tissue factor bearing (CD142+) circulating procoagulant EVs in pre-
eclamptic patients (n = 10) and healthy controls (n = 13). * p < 0,05. 
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healthy pregnant women a significantly higher amount of tissue factor 
positive, thrombogenic, platelet-derived extracellular vesicles were 
present in the plasma of pregnant women with preeclampsia, a finding, 
which can have significant translational clinical ramification. 
The present study was undertaken on pregnant women in pre-
eclamptic conditions as indicated by their parameters compared to those 
of pregnancy-matched healthy women included in Table 1. Their plasma 
samples were collected and analyzed for platelets, and various platelet- 
derived extracellular vesicles. 
The maintenance of hemostatic equilibrium is of utmost importance 
to maintain healthy blood circulation, which can be a major challenge 
during pregnancy. Even healthy pregnant women can develop throm-
boembolic complications four to five times more often during the 
pregnancy compared to non-pregnant women (Eichinger et al., 1999). 
About eighty percent of these thromboembolic events are located on the 
venous side of circulation and about twenty percent occur in the arteries. 
The procoagulant state of pregnancy can be considered as a protective 
mechanism to prevent major blood loss during and after the childbirth 
(James, 2009). 
Unfortunately, the occurrence of preeclampsia is steadily rising in 
the developed countries, thereby increasing the risk for maternal and 
fetal morbidity and mortality (Li et al., 2018). Preeclampsia may pose 
women to a fivefold increase of risk for pregnancy associated venous 
thromboembolism compared to the general pregnant population, mainly 
in the postpartum period (Egan et al., 2015). 
Generalized activation of the coagulation system can complicate 
severe preeclampsia or HELLP syndrome (Bossung et al., 2020). 
Disseminated intravascular coagulation (DIC) is a secondary disorder 
caused by the over-activation of coagulation system that causes the 
consumption of coagulation factors, platelets and fibrinolytic proteins 
leading to uncontrollable, multifocal bleeding. DIC is mostly associated 
with adverse maternal outcome, including massive transfusions, hys-
terectomy, and even death (Erez et al., 2015). 
More than forty years ago Redman et al. have described the increased 
platelet consumption as an early feature of preeclampsia (Redman et al., 
1978). In line with this early finding, we also observed significantly 
decreased platelet count in the preeclamptic group. Platelet lifespan is 
significantly shorter in preeclampsia than in uncomplicated pregnancy 
(Rákóczi et al., 1979). Some of the platelets’ properties, such as mean 
platelet volume (MPV) and platelet distribution width (PDW) are 
routinely measured by blood count analyzers and are significantly 
increased in preeclampsia compared to normal pregnancy (Freitas et al., 
2013). Platelet age correlates inversely with the MPV, thus the younger 
the platelets are, the higher the MPV is (Giles, 1981). MPV is known to 
increase due to the rapid turnover and activation of platelets thus larger 
platelets are more prone to aggregation (Park et al., 2002). Out of all 
platelets, younger platelets have the strongest adhesive and thrombo-
genic function (Thattaliyath et al., 2005). According to a recent 
meta-analysis there is strong evidence, that increased platelet activation 
can be detected in preeclampsia and MPV is significantly increased in 
preeclamptic women compared to healthy pregnant women (Jakobsen 
et al., 2019). 
Platelet-derived extracellular vesicles are generally considered as a 
marker of platelet activation (Antwi-Baffour et al., 2015). This process 
leads to several changes on the cell surface markers. Phosphatidylserine 
(PS) is normally located in the cytoplasmic surface of the platelet 
membrane and platelet activation causes externalization of PS. The 
exposed PS then activates blood coagulation by enhancing factor 
Xa-factor Va binding (Lentz, 2003). The significantly higher ratio of PS 
expressing platelets and tissue factor expressing platelet derived EVs in 
the plasma of preeclamptic women vs. healthy controls found in our 
study may explain the hypercoagulable state observed in preeclampsia. 
Nevertheless, the exact role of EVs has not been yet entirely elucidated. 
Yi et al. have studied the expression levels of CD41a, CD62 P and 
CD63 of platelets and found that they were higher in preeclampsia than 
in healthy pregnant women (Yi et al., 2003). We have also found higher 
albeit not significantly elevated CD63 expression of PEVs’, but the 
amount of CD41a and CD62 P positive PEVs’ turned out to be markedly 
lower in preeclamptic patients. This may highlight the difference be-
tween the expression patterns of these glycoproteins between platelets 
and platelet-derived extracellular vesicles. 
Tissue factor is an integral membrane receptor for coagulation Factor 
VII. It is constitutively expressed by cells surrounding blood vessels but 
it can be also detected on the surface of circulating extracellular vesicles 
(Bao et al., 2018). Both tissue factor bearing cells and extracellular 
vesicles are strong activators of extrinsic coagulation cascade (Kleinjan 
et al., 2012). Elevated levels of TF expressing EVs have already been 
detected in hypertensive disorders of pregnancy previously (Mackman, 
2009; Del Conde et al., 2005), including higher amount of TF-positive 
syncytiotrophoblast micro-vesicles, which enhance 
Fig. 4. Circulating platelet derived EVs: Significantly lower amount of CD41a 
+ platelet derived EVs (a) and CD62P+/CD41a + activated platelet derived EVs 
(b) could be detected in the plasma of preeclamptic patients compared to third 
trimester pregnant-matched group. (medians and IQRs; * p < 0.05). 
Fig. 5. The median amount of CD63 (tetraspanin) positive activated platelet 
derived extracellular vesicles in preeclampsia (n = 13) and healthy controls (n 
= 13). (medians and IQRs, p = 0.15). ns = not significant. 
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thrombin-formation in preeclampsia. Extracellular vesicles are hypoth-
esized to exhibit their procoagulant effect by their tissue factor content 
(Gardiner et al., 2011). One of the novel findings our study is that we 
could detect significantly higher amount of TF-positive platelet derived 
EVs in preeclampsia for the first time. According to our observations, the 
absolute amount of circulating CD41a + platelet derived EVs and 
CD41a+/CD62P + EVs produced by activated thrombocytes were 
significantly lower in the plasma of preeclamptic women than in healthy 
pregnant women. 
CD62 P is a cell adhesion molecule (P-selectin, GMP-140, PADGEM), 
which plays an essential role in the initial recruitment of leukocytes, in 
platelet aggregation, in platelet-leukocyte interactions and in the 
adhesion of those to the endothelium as it is translocated from the 
cytoplasmic granules to the external cell membrane (Cambien and 
Wagner, 2004). The majority of previous studies have reported 
increased circulating platelet-monocyte aggregates during preeclampsia 
(Macey et al., 2010; Holthe et al., 2005). As platelets bind to monocytes 
predominantly via P-selectin–P-selectin glycoprotein ligand-1 
(CD62P-PSGL-1) pathway (Bournazos et al., 2008), it may explain the 
contradiction between the elevated ratio of circulating activated plate-
lets and the decreased CD62P + P-EV count. The lower count of acti-
vated platelet derived EVs may probably be due to the P-selectin 
mediated aggregate formation in the preeclamptic group. 
CD63 is a lysosomal membrane glycoprotein, which belongs to tet-
raspanin family. CD63 has been identified as a platelet activation 
molecule which regulates gpIIb/IIIa function in platelets to aid the 
stability of the newly formed clots (Goschnick et al., 2006). We have 
found a trend of increased amount of CD63-positive platelet derived EVs 
in the preeclamptic samples, which further confirms the presence of 
increased platelet activation. 
All these findings are in line with the idea that preeclampsia alters 
the procoagulant characteristics of blood and the number of circulating 
platelet derived extracellular vesicles by increased platelet activation 
and tissue factor expression. These changes may contribute to the he-
mostatic disturbances in preeclampsia, such as thrombotic events in the 
venous and arterial circulation. Moreover, blocking cerebral micro-
vessels could explain seizures observed in eclampsia. Previous studies 
proposed another mechanism by which platelet derived microparticles 
may contribute to the development of hypertension, suggesting the 
presence of a positive feedback mechanism in preeclampsia (Bao et al., 
2018). In addition, maternal extracellular vesicles and platelets may 
promote preeclampsia via inflammasome activation in trophoblasts 
(Kohli et al., 2016). 
Recent evidence suggests that extracellular vesicles can transfer in-
formation to adjacent and remote areas by eliciting surface receptor 
activation and unloading the vesicular cargo into the recipient cell by 
internalization. In pathological conditions associated with tissue hyp-
oxia, acidosis and oxidative stress, such as cardiac infarction, stroke, and 
abnormal cell proliferation (tumor formation) the degree of vesiculation 
has been shown to rise in a HIF-1α dependent manner (Belting and 
Christianson, 2015). 
The increased release of thrombogenic extracellular vesicles in pre-
eclampsia can lead to a hypercoagulable state as shown in the present 
study. Indeed, the main features of preeclampsia are uteroplacental 
hypoxia and oxidative stress both of which are present in tumor devel-
opment pointing to the common mechanism of vesiculation. These 
findings may promote further research in this field and will support 
clinical decision making regarding diagnosis and treatment. 
Finally, it is tempting to entertain the idea that similar disturbed 
hemostatic conditions can develop in the novel coronavirus disease 
Covid-19 (SARS-CoV-2), such as coagulopathy, and disseminated 
intravascular coagulation (DIC)-like massive intravascular clot forma-
tion suggesting common mechanism of actions and perhaps similar 
therapeutic potentials (Ogawa et al., 2021; Taherifard et al., 2021). 
Limitation of the study: The occurrence of preeclampsia was mod-
erate at our clinic, which limited the sample size, thus we consider this 
investigation as a pilot study generating hypothesis. 
In conclusion, to the best of our knowledge, this is the first study 
analyzing the markers of platelet-derived extracellular vesicles in pre-
eclampsia, and we have detected a significantly higher amount of tissue 
factor-positive thrombogenic platelet derived extracellular vesicles in 
the plasma of preeclamptic women compared to pregnancy-matched 
healthy women. Thus, we propose that increased platelet activation 
and tissue factor expression of platelet-derived extracellular vesicles 
may contribute to the hypercoagulable state observed in preeclampsia. 
This idea corresponds to the prothrombotic state and consumptive 
coagulopathy observed previously in preeclampsia. Further investiga-
tion of thrombocyte function might help us to better understanding the 
underlying mechanisms responsible for the development of the disease 
as well as to find new diagnostic biomarkers and potential therapeutic 
strategies for preeclampsia. 
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